Core Viewpoint - Avantor, Inc. reported a decline in adjusted earnings per share (EPS) for Q2 2024, but the results exceeded consensus estimates despite a drop in revenue and segmental sales [1][2][9]. Revenue Details - Revenues for Q2 2024 totaled $1.7 billion, reflecting a year-over-year decrease of 2.4% and missing the Zacks Consensus Estimate [2]. - Foreign currency translation negatively impacted revenues by 0.4%, leading to an organic sales decline of 2% [2]. Segmental Analysis - Avantor restructured its reporting segments into two: Laboratory Solutions and Bioscience Production, effective January 1, 2024 [3]. - Laboratory Solutions reported net sales of $1.16 billion, down 3.2% year over year, with organic sales falling 2.7% due to inventory destocking and cautious spending by biopharma customers [3]. - Bioscience Production's net sales were $547.1 million, a decrease of 0.5% year over year, with organic sales down 0.3% [3]. Margin Analysis - Gross profit for the quarter declined 1.4% to $581.5 million, while gross margin expanded by 30 basis points to 34.1% [5]. - Selling, general, and administrative expenses increased by 13.5% year over year to $405.7 million [5]. - Operating profit rose significantly by 145.2% to $175.8 million, although the operating margin contracted by 620 basis points to 10.32% [5]. Financial Position - At the end of Q2 2024, Avantor had cash and cash equivalents of $272.6 million, up from $234.9 million at the end of Q1 [6]. - Total debt decreased to $5.12 billion from $5.3 billion at the end of Q1 2024 [6]. - Net cash provided by operating activities was $281.1 million, compared to $168.2 million a year ago [6]. Guidance - Avantor maintained its 2024 revenue outlook, projecting between $6.85 billion and $7.06 billion, which represents a decline of 1.7% to an increase of 1.3% from 2023 levels [7]. - The company expects organic revenues to decline by 2% to increase by 1% for the full year, with a similar expectation for Q3 [8]. - Adjusted EPS is projected to be between 96 cents and $1.04 for the full year, with the consensus estimate at $1 [8]. Additional Insights - Avantor's commercial intensity led to share gains through new contract wins and expanded customer relationships in various markets [4]. - The company launched several innovative products aimed at enhancing gene therapy processes and opened a new customer service center in Mexico to improve service levels [10]. - Avantor remains committed to sustainability, as evidenced by its annual sustainability report and ongoing cost transformation initiatives [11].

Core Viewpoint - Avantor, Inc. reported better-than-expected second-quarter earnings, with adjusted earnings of 25 cents per share, surpassing market estimates of 23 cents per share, and sales of $1.703 billion, aligning with estimates [1] Financial Performance - The company achieved a sequential improvement in all key financial metrics, with a notable increase in bioprocessing revenue contributing to over 100 basis points of sequential Adjusted EBITDA margin expansion [1] - Free cash flow conversion exceeded 100% due to disciplined working capital management [1] Management Commentary - Michael Stubblefield, President and CEO, reaffirmed the fiscal year 2024 guidance and emphasized the focus on executing the long-term growth strategy and delivering value to customers and shareholders [1] Stock Performance - Following the earnings announcement, Avantor shares increased by 12.2%, closing at $25.60 [1] Analyst Ratings - Baird analyst Catherine Schulte maintained an Outperform rating on Avantor, raising the price target from $26 to $27 [2] - Stifel analyst Daniel Arias maintained a Buy rating, increasing the price target from $27 to $28 [2]

Q2 2024 Financial Performance - Reported Revenue was $1.703 billion, a decrease of 2.0% compared to Q2 2023's $1.744 billion[12] - Organic growth decreased by 9.1%[12] - Adjusted Gross Profit was $583 million, representing 34.2% of revenues[12] - Adjusted EBITDA was $306 million, or 17.9% of revenues[12] - Adjusted Earnings Per Share (EPS) was $0.25[12] - Free Cash Flow was $235 million[12] Segment Performance - Laboratory Solutions reported revenue of $1.156 billion with organic growth of -2.7% and adjusted operating margin of 13.1%[16] - Bioscience Production reported revenue of $547 million with organic growth of -0.3% and adjusted operating margin of 26.3%[17] Full Year 2024 Guidance (Reaffirmed) - Organic Revenue Growth is projected to be between -2% and +1%[19] - Reported Revenue is expected to be between $6.85 billion and $7.06 billion, representing a reported growth of -1.7% to +1.3%[19] - Adjusted EBITDA Margin is projected to be between 17.4% and 17.9%, resulting in Adjusted EBITDA of $1.19 billion to $1.26 billion[19] - Adjusted EPS is expected to be between $0.96 and $1.04[19] - Free Cash Flow is projected to be between $600 million and $650 million, excluding approximately $100 million in cash costs related to the cost transformation initiative[19]

Avantor Inc. (NYSE:AVTR) Q2 2024 Earnings Conference Call July 26, 2024 8:00 AM ET Company Participants Christina Jones - VP, IR Michael Stubblefield - President & CEO Brent Jones - EVP & CFO Conference Call Participants Vijay Kumar - Evercore ISI Tycho Peterson - Jefferies Douglas Schenkel - Wolfe Research Daniel Brennan - TD Cowen Rachel Vatnsdal - JPMorgan Michael Ryskin - Bank of America Jack Meehan - Nephron Research Matthew Sykes - Goldman Sachs Conor McNamara - RBC Capital Markets Luke Sergott - Barc ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ━━━━━━━━━ FORM 10-Q ━━━━━━━━━ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission file number: 001-38912 Avantor, Inc. (Exact name of registrant as specified in its charter) Delaware 82-2758923 (Stat ...

Avantor, Inc. (AVTR) came out with quarterly earnings of $0.25 per share, beating the Zacks Consensus Estimate of $0.23 per share. This compares to earnings of $0.28 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 8.70%. A quarter ago, it was expected that this company would post earnings of $0.20 per share when it actually produced earnings of $0.22, delivering a surprise of 10%.Over the last four quarters, the company has su ...

Exhibit 99.1 Avantor® Reports Second Quarter 2024 Results • Net sales of $1.70 billion, decrease of 2.4%; organic decline of 2.0% • Net income of $93 million; Adjusted EBITDA of $306 million • Diluted GAAP EPS of $0.14; adjusted EPS of $0.25 • Operating cash flow of $281 million; free cash flow of $235 million RADNOR, Pa. – July 26, 2024 – Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, toda ...

Net sales of $1.70 billion, decrease of 2.4%; organic decline of 2.0%Net income of $93 million; Adjusted EBITDA of $306 millionDiluted GAAP EPS of $0.14; adjusted EPS of $0.25Operating cash flow of $281 million; free cash flow of $235 millionRADNOR, Pa., July 26, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today reported financial results for its second fiscal quarte ...

NEW YORK, July 23, 2024 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400 and S&P SmallCap 600: Avantor Inc. (NYSE:AVTR) will replace QuidelOrtho Corp. (NASD:QDEL) in the S&P MidCap 400, and QuidelOrtho will replace Hibbett Inc. (NASD:HIBB) in the S&P SmallCap 600 effective prior to the opening of trading on Friday, July 26. JD Sports Fashion Plc (XLON: JD) is acquiring Hibbett in a deal expected to close soon pending final closing conditions. Schneider National In ...

Avantor, Inc. (AVTR) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended June 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on July 26. On ...